Pertussis: Current concepts of pathogenesis and prevention

Pediatric Infectious Disease Journal

Volumn 16, Issue 4 SUPPL., 1997, Pages

  Hewlett, Erik L ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; PERTUSSIS VACCINE;

BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; HUMAN; INFECTION PREVENTION; PATHOGENESIS; PERTUSSIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CLINICAL TRIALS; HUMANS; PERTUSSIS VACCINE; RESPIRATORY SYSTEM; VACCINATION; VIRULENCE; WHOOPING COUGH;

EID: 0030958171     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704001-00002     Document Type: Review

References (72)

1. Cherry JD, Brunell PA, Golden GS, et al. Report of the task force on pertussis and pertussis immunization: 1988. Pediatrics 1988;81:939-84.
2. Golden GS. Pertussis vaccine and injury to the brain. J Pediatr 1990;116:854-61.
3. Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines: Institute of Medicine. Washington, DC: National Academy Press, 1991.
4. Hodder SL, Mortimer EA Jr. Epidemiology of pertussis and reactions in pertussis vaccine. Epidemiol Rev 1992;14:243-67.
5. Stratton KR, Howe CJ, Johnston RB, eds. DPT vaccine and chronic nervous system dysfunction: a new analysis: Institute of Medicine, Committee to Study New Research on Vaccines. Washington, DC: National Academy Press, 1994.
6. Cherry JD. Pertussis vaccine encephalopathy: it is time to recognize it as the myth that it is. JAMA 1990;263:1679-80.
7. Hewlett EL. Bordetella pertussis and the central nervous system. In: Scheld WM, Whitley RJ, Durack DT, eds. Infections of the central nervous system. 2nd ed. New York: Raven Press, 1996:655-66.
8. Marwick C. Acellular pertussis vaccine is licensed for infants. JAMA 1996;276:516-8.
9. Food and Drug Administration. Approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus and pertussis vaccination series. MMWR 1996;45: 676-7.
10. Weiss AA, Hewlett EL. Virulence factors of Bordetella pertussis. Annu Rev Microbiol 1986;40:661-6.
11. Wardlaw AC, Parton R, eds. Pathogenesis and immunity in pertussis. New York: Wiley, 1988.
12. Hewlett EL. Bordetella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:2078-83.
13. Tuomanen E. Bordetella pertussis adhesins. In: Wardlaw AC, Parton R, eds. Pathogenesis and immunity in pertussis. New York: Wiley, 1988:75-94.
14. Finn TM, Stevens LA. Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant. Mol Microbiol 1995;16:625-34.
15. Tuomanen E, Weiss A. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis 1985;152:118-25.
16. Redhead K. An assay of Bordetella pertussis adhesion to tissue culture cells. J Med Microbiol 1985;19:99-108.
17. Urisu A, Cowell JL, Manclark CR. Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect Immun 1986;52:695-701.
18. Relman DA, Domenighi M, Tuomanen E, et al. Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc Natl Acad Sci USA 1989;86:2637-41.
19. Leininger E, Roberts M, Kenimer JG, et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci USA 1991;88:345-9.
20. Locht C, Bertin P, Menozzi FD, et al. The filamentous hemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp. Mol Microbiol 1993;9:653-60.
21. Mooi FR, Jansen WH, Brunnings H, et al. Construction and analysis of Bordetella pertussis mutants defective in the production of Limbrine. Microbiol Pathog 1992;12:127-35.
22. 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 1990;61:1375-82.
23. Weiss AA, Hewlett EL, Myers GA, et al. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun 1983;42:33-41.
24. Miller J, Mekalanos JJ, Falkow S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 1989;243:916-22.
25. Gross R, Carbonetti NH. Differential regulation of Bordetella pertussis virulence factors. Int J Med Microbiol Virol Parasitol Infect Dis 1993;278:177-86.
26. Scarlato V, Arico B, Prugnola A, et al. Sequential activation and environmental regulation of the virulence genes in Bordetella pertussis. EMBO J 1991;10:3971-5.
27. Cookson BT, Tyler AN, Goldman WE. Primary structure of the peptidoglycan-derived tracheal cytotoxin of Bordetella pertussis. Biochemistry 1989;28:1744-9.
28. Luker KE, Collier JL, Kolodziej EW, et al. Bordetella pertussis tracheal cytotoxin and other muramyl peptides: distinct structure-activity relationships for respiratory epithelial cytopathology. Proc Natl Acad Sci USA 1993;90:2365-9.
29. Heiss LN, Lancaster JR, Corbett JA, et al. Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertussis. Proc Natl Acad Sci USA 1994;91:267-70.
30. Wilson R, Read R, Thomas M, et al. Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro. Infect Immun 1991;59:337-45.
31. Melly MA, McGee AZ, Rosenthal RS. Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa. J Infect Dis 1984;149: 378-86.
32. Confer DL, Eaton JW. Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 1982;217:948-50.
33. Hewlett EL, Gordon VM. Adenylate cyclase toxin of Bordetella pertussis. In: Wardlaw AC, Parton R, eds. Pathogenesis and immunity in pertussis. New York: Wiley 1988:193-210.
34. Mouallem M, Farfel Z, Hanski E. Bordetella pertussis adenylate cyclase toxin: intoxication of host cells by bacterial invasion. Infect Immun 1990;58:3759-64.
35. Pearson RD, Symes P, Conboy M, et al. Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. J Immunol 1987;139:2749-54.
36. Khelef N, Guiso N. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin. FEMS Microbiol Lett 1995;134:27-32.
37. Farfel Z, Konen S, Wiertz E, et al. Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination. J Med Microbiol 1990;32:173-7.
38. Arciniega JL, Hewlett, EL, Johnson FD, et al. Human serological response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis 1991; 163:135-42.
39. Guiso N, Grimprel E, Anjola I, et al. Western blot analysis of antibody responses of young infants to pertussis infection. Eur J Clin Microbiol Infect Dis 1990;12:596-600.
40. Betsou F, Sebo P, Guiso N. The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun 1995;63:3309-15.
41. Edwards KM. Acellular pertussis vaccines: a solution to the pertussis problem? J Infect Dis 1993;168:15-20.
42. Hewlett EL, Cherry JD. New and improved vaccines against pertussis. In: Levine MM, Woodrow G, Kaper JB, Cobon GS, eds. New generation vaccines. 2nd ed. New York: Dekker (in press).
43. Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis 1984;3:467-86.
44. Robbins JB, Pittman M, Trollfors B, et al. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis 1993;12:795-807.
45. Ui M. The multiple biological activities of pertussis toxin. In: Wardlaw AC, Parton R, eds. Pathogenesis and immunity in pertussis. New York: Wiley, 1988:121-46.
46. Ui M. Pertussis toxin as a valuable probe for G-protein involvement in signal transduction. In: Moss J, Vaughan M, eds. ADP-ribosylating toxins and G proteins. Washington, DC: American Society for Microbiology, 1990:45-78.
47. Toyota T, Kai Y, Kazizaki M, et al. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (Phase 1 studies). Tohuku J Exp Med 1980;130: 105-16.
48. Arico B, Rappuoli R. Bordetella pertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 1987;169:2847-53.
49. Wirsing von Konig CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. Eur J Clin Microbiol Infect Dis 1991;13:455-8.
50. Iwata S, Aoyama T, Goto A, et al. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. Dev Biol Stand 1991;73:333-41.
51. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep 1965;80:365-9.
52. Gan VN, Murphy TV. Pertussis in hospitalized children. Am J Dis Child 1990;144:1130-4.
53. Wortis N, Strebel PM, Wharton M, et al. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 1996;97:607-12.
54. Ewanowich CA, Melton AR, Weiss AA, et al. Invasion of HeLa 229 cells by virulent Bordetella pertussis. Infect Immun 1989;57:2698-704.
55. Friedman RL, Nordensson K, Wilson L, et al. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect Immun 1992;60:4578-85.
56. Cheers C, Gray DF. Macrophage behavior during the complaisant phase of murine pertussis. Immunology 1969;17: 875-87.
57. Bromberg K, Tannis G, Steiner P. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun 1991;59:4714-9.
58. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988;1:955-60.
59. Storsaeter J, Hallander H, Farrington CP, et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish Phase III trial. Vaccine 1990;8:457-61.
60. The Göteborg Pertussis Vaccine Study. Clinical trials of a monocomponent pertussis toxoid vaccine (NICHD Ptxd): a technical report, 1995.
61. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
62. First International Pediatric Infectious Disease Conference, Monterey, CA, September 21 to 22, 1995.
63. Hewlett EL. Preparation and composition of acellular pertussis vaccines: considerations of potential effects on vaccine efficacy. Dev Biol Stand 1996;89:131-9.
64. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996;334: 3439-55.
65. Efficacy trial of acellular pertussis vaccines. Technical Report Trial 1. Swedish Institute for Infectious Disease Control, 1995.
66. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
67. Schmitt HJ, Wirsing von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
68. WHO meeting on case definition of pertussis, Geneva, Switzerland, January 10 to 11, MIM/EPI/Pert/9.1. Geneva; WHO, 1991.
69. Peppoloni S, Nencioni L, Di Tommasto A, et al. Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect Immun 1991;59:3768-73.
70. Mills KHG, Redhead K. Cellular immunity in pertussis. J Med Microbiol 1993;39:163-4.
71. Petersen JW. Cellular immunity in relation to pertussis vaccination and infection. Dan Med Bull 1995;42:121-40.
72. Zepp P, Knuf M, Habermehl P, et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996; 64:4078-84.